Form N-VP/A TALCOTT RESOLUTION LIFE
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailTalcott Resolution Life Insurance Company
Talcott Resolution Life Insurance Company Separate Account Two:
Director Access Series II/IIR
The contract was previously sold under various marketing names depending on which distribution partner sold the contract and/or when the product was sold. These marketing names include: Director Access Series II/IIR and Director Choice Access Series II/IIR.
Talcott Resolution Life Insurance Company
Talcott Resolution Life Insurance Company Separate Account Two:
Director Access Series I/IR
The contract was previously sold under various marketing names depending on which distribution partner sold the contract and/or when the product was sold. These marketing names include: Director Access Series I/IR and Director Choice Access Series I/IR.
Supplement dated August 25, 2025 to the product notice dated April 30, 2025
The following supplements and amends the above mentioned product notice. Please read this supplement and retain it for future reference. Special terms not defined in this supplement have the same meanings as in your product notice.
In Appendix A - Funds Available Under the Contract: current expenses for certain funds are updated as follows:
| Fund and Adviser/Subadviser | Current Expenses | ||||
| AB VPS Relative Value Portfolio - Class B Adviser: AllianceBernstein, L.P. | 0.86% | ||||
HV-8194
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- X-SENSE XR0A-iR Smart Radon Detector Now Available on Lowes.com
- COP31: Planet Classroom Unveils 10 Films Exploring Climate Solutions, AI and Youth Action
- Alethio Therapeutics Raises $90 Million (£67 Million) in Oversubscribed Series A Financing to Advance a New Generation of Therapies for Myeloproliferative Neoplasms
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
